GET IN TOUCH WITH US:
Click here to find out what our clients think about our STRATEGY MEETINGS
ONLINE CLINICAL OPERATIONS
STRATEGY MEETING 2020
16th November 2020, Monday
1:00pm - 6:00pm UK | 8:00am - 1:00pm NY
UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com Connect with us
SPONSORS
AGENDA
KEYNOTE PRESENTATION TRACK 1:
Risk Based Monitoring TRACK 2:
Patient Recruitment /
Patient Centricity & Virtual Trials TRACK 3: Emerging Biopharma TRACK 4: Clinical Outsourcing TRACK 5: Clinical Data/RWE TRACK 6:
A.I & Disruptive Technology 2019 ATTENDEES
CONTRIBUTORS TO THE AGENDA
Guillermo
Caletti
Head of Clinical Operations
Boehringer Ingelheim
Prasun Mishra
Chief Executive Officer
Agility
Pharmaceuticals
Magali Taiel
Chief Medical Officer
Gensight Biologics
Pernilla
Sandwall
Chief Operating Officer
InDex Pharmaceuticals
Eyal Ron
CTO AcuityBioFrank Leu
Chief Executive Officer NovapeuticsVladimir
Bulatov
Chief Scientific Officer
Novartis Russia
William
Blumentals
Head of Pharmacoepidemiology Sanofi GenzymeOUR UNIQUE ONLINE MEETING FORMAT
Roundtable Discussions
These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.
Personalised Agenda
Each delegate receives a personalised agenda with the roundtable discussions that you
choose. You only attend sessions and meetings that fit your challenges and interests,
ensuring your time spent on the online platform is focused and well-utilised.
Innovative Solutions
Whatever your challenge may be, let our official event partners find the solution. Gain access to our carefully selected solution providers and find your next strategic partner that will help take your business to the next level.
Strategic Networking
Strategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.
OUR VISION
OUR MISSION
To be a platform for creating life-saving therapies and to facilitate
the creation of a completely patient centric pharmaceutical industry.
By encouraging key leaders and their companies to put the patient
at the very heart beat of every innovation. Sharing valuable
insights and strategies to assist in the discovery, development and
commercialisation of life saving therapies.
UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com
SPONSORS
OUR
02
GO TO MENU PREVIOUS PAGE NEXT PAGE
LEAD SPONSOR
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. Formed through the merger of IMS Health and Quintiles, IQVIA has approximately 67,000 employees worldwide. Learn more at www.iqvia.com.
Pro-ficiency is the leader in providing simulation training and communication tools to remotely manage the performance of clinical trial sites. Through the power of simulation training, Sponsors can boost remote site performance to increase enrollment and study quality. Using training as an engagement tool creates additional value beyond compliance through actionable analytics. As the chosen training provider to the ACRP, Po-ficiency has trained 60,000+ clinical researchers for hundreds of global studies. Pro-ficiency bridges the gap between study teams and sites with remote training and study start tools, allowing Sponsors to monitor and track compliance remotely.
Cmed is an innovative full-service CRO where technology meets expertise in data science and analytics.Established in 2000, Cmed brings together experienced people and technology to provide sponsors with a friendly, proactive service delivered using advanced clinical data capture, management and reporting software and processes. We deliver flexible partnering solutions with 140 strategically located Data experts and hundreds of trials managed to date. We work with advanced technologies including encapsia, the powerful data collection and management solution for clinical trials.
CO-HOST SPONSORS
ARENSIA EXPLORATORY MEDICINE is a German operator of proprietary Research Clinics in Eastern Europe, dedicated to performing complex Phase Ib, IIa and PROOF-OF-CONCEPT clinical trials with novel molecules, involving patients across numerous disease areas. Given the outstanding patient recruitment rates achieved by ARENSIA clinics, we are able to dramatically reduce the overall number of sites, countries and recruitment periods for any early phase patient trial. Sponsors regard the recruiting speed and the data quality of ARENSIA as disruptive added value, providing them with a strategic advantage. As a testament to the excellent performance, ARENSIA is trusted by the world’s largest pharmaceutical and biotechnology companies, by global CROs, as well as by venture capital funds aiming to maximize their return of investment in small/virtual biotech companies.
PRO-PARTNERS
ONLINE CLINICAL OPERATIONS
STRATEGY MEETING 2020
THOUGHT LEADER
SanaClis was founded in 2000 by seasoned industry experts all of whom have had executive level positions in leading pharma companies and large global CROs and is one of the very few full-service CROs for clinical trials mainly in Central and Eastern Europe (CEE) offering a comprehensive range of full-services including: regulatory, clinical monitoring, IMP & CTS management, customs clearance & brokerage, site contracting & payments, project management, quality management, training, central laboratory Russia - including bioequivalence studies, data management, statistics and medical writing. Its facilities, depots and processes meet the most stringent international standards and local requirements. Moreover, SanaClis developed its own software solution to track warehouse operations in real time internally and externally for clients.
UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com
AGENDA
PART 1
03
GO TO MENU PREVIOUS PAGE NEXT PAGE
ONLINE CLINICAL OPERATIONS
STRATEGY MEETING 2020
TRACK & ROOM
01 -
RISK BASED MONITORING02 -
PATIENT CENTRICITY & PATIENT RECRUITMENT /VIRTUAL TRIALS
03 -
EMERGING BIOPHARMA04 -
CLINICAL OUTSOURCING05 -
CLINICAL DATA/RWE06 -
A.I & DISRUPTIVE TECHNOLOGYTIME (UK) TIME (NY)
1:00pm -
1:30pm UK 8:00am - 8:30am NY
KEYNOTE PRESENTATION
COVID-19 and the Emerging New Normal for Clinical Trials
Teresa Lamantia — VP, Global Quality and Transformation, IQVIA
1:30pm -
1:45pm UK 8:30am - 8:45am NY BREAK
1:45pm -
2:45pm UK 8:45am - 9:45am NY
Developing and implementing ML/AI capabilities to improve risk-based quality management
Justin Starks —
Head of Innovation, Trial Monitoring,
Novartis
GC – Patient Recruitment
Guillermo Caletti —
Head of Clinical Operations,
Boehringer Ingelheim
Developing a COVID19 vaccine
Jessica Lee —
SVP Clinical Operations & Global Integration,
Inovio Pharmaceuticals
Ensuring strong and efficient vendor oversight and
communication
Magali Taiel —
Chief Medical Officer,
Gensight Biologics
Can we generate real world evidence within registration studies?
Arun Mistry —
Therapeutic Area Head,
Mereo BioPharma
AI and Disruptive Technologies in Accelerating Clinical Trials
Prasun Mishra —
Chief Executive Officer,
Agility Pharmaceuticals
2:45pm -
3:15pm UK 9:45am - 10:15am NY
KEYNOTE PRESENTATION How are RWE studies evolving?
Vladimir Bulatov — Chief Scientific Officer, Novartis Russia
3:15pm -
4:15pm UK 10:15am - 11:15am NY Associate Director, Process, Zabir Macci —
Technology and Analytics Centralized Monitoring Services,
Clinical Operations, IQVIA
Christopher Varner —
Project Lead, Virtual Trials,
IQVIA Global Business Development John Murray — Director, SanaClis s.r.o. &
Ann Baker —
VP, R&D Consulting,
IQVIA
Stephanie Langouet —
Chief Operations Officer,
Cmed
David Hadden —
Co-Founder and Chief-Game-Changer, Pro-ficiency
4:15pm -
4:45pm UK 11:15am - 11:45am NY
KEYNOTE PRESENTATION
New Trial Designs in Early Drug Development: Challenges and Future Visions
Claudia Hesselmann, PhD — Co-Founder & Managing Director, ARENSIA
4:45pm -
5:00pm UK 11:45am - 12:00pm NY BREAK
5:00pm -
6:00pm UK 12:00pm - 1:00pm NY
How to develop a Monitoring Plan to incorporate a risk-based approach?
Jonathan Rabinowitz —
Professor, Bar-Ilan University
Optimizing patient recruitment by utilising digital health, RWE as well as traditional methods
Pernilla Sandwall —
Chief Operating Officer,
InDex Pharmaceuticals
Clinical Research in the Time of COVID-19
Kylie Gyertson —
Head of Cancer Clinical Trials,
NHS Foundation Trust
Using Innovative Tools to Make a CRO a Trusted Partner
Eyal Ron —
CTO, AcuityBio
Matching Electronic Health Records to RWD to improve outcomes
William Blumentals —
Head of Pharmacoepidemiology,
Sanofi Genzyme
Adopting Disruptive Technologies in Drug Development are not
Optional for Survival
Frank Leu —
Chief Executive Officer,
Novapeutics
UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com
KEYNOTE
PRESENTATION
04
GO TO MENU PREVIOUS PAGE NEXT PAGE
ONLINE CLINICAL OPERATIONS
STRATEGY MEETING 2020
Teresa Lamantia
VP, Global Quality and Transformation
IQVIA
COVID-19 and the Emerging New
Normal for Clinical Trials
1:00pm - 1:30pm UK 8:00am - 8:30am NY 1ST KEYNOTE PRESENTATION 2:45pm - 3:15pm UK 9:45am - 10:15am NY
Vladimir Bulatov
Chief Scientific Officer
Novartis Russia
How are RWE studies evolving?
2ND KEYNOTE PRESENTATION 4:15pm - 4:45pm UK 11:15am - 11:45am NY
Claudia
Hesselmann, PhD
Co-Founder & Managing Director ARENSIANew Trial Designs in Early Drug
Development: Challenges and
Future Visions
3RD KEYNOTE PRESENTATION
• Introductory picture on Master Protocols • Global examples and case studies from ARENSIA´s experience with adaptive protocol designs and lesson learned in context of COVID-19 pandemic
• What “fast-track” elements from
COVID-19 research will persevere in design and implementation of future protocols • Visions in drug development: what type of protocols will come next? will a
industry-wide global platform protocol become the new standard?
• Novel protocol design and regulatory approaches
• Patient-centered recruitment and visit strategies
• Onsite and remote monitoring trends • Technology innovation
• Broader use of RWE studies –
to optimize R&D, support registration, facilitate reimbursement
• Innovative study designs, including predictive models, enriched studies, implementation science
• Use of advanced analytics – AI, machine learning etc.
• Broader use of new data sources, like social media, e-records, wearable devices
• RWE studies in partnerships
with regulators, academia, patient organizations
UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com
TRACK 1
Risk Based Monitoring
05
GO TO MENU PREVIOUS PAGE NEXT PAGE
ONLINE CLINICAL OPERATIONS
STRATEGY MEETING 2020
Justin Starks
Head of Innovation, Trial Monitoring NovartisJonathan Rabinowitz
Professor Bar-Ilan UniversityDeveloping and implementing ML/AI capabilities
to improve risk-based quality management
1:45pm - 2:45pm UK 8:45am - 9:45am NY
3:15pm - 4:15pm UK 10:15am - 11:15am NY
5:00pm - 6:00pm UK 12:00pm - 1:00pm NY
Zabir Macci
Associate Director, Process, Technology and Analytics Centralized Monitoring Services,
Clinical Operations
IQVIA
A definitive approach to monitoring during
unprecedented times – RBM and beyond
SPONSOR
How to develop a Monitoring Plan to incorporate a
risk-based approach?
• Understanding regulatory rational for RBM
• How to see the potential of multitasking existing systems for RBM
• Examples of using existing systems creatively as RBM tools
• The opportunities that the application of machine learning and big data present in the risk-based quality management (RBQM)
• The practical challenges of development and implementation
• The path forward
• How has COVID disrupted the monitoring model – inaccessibility to site, inaccessibility to patients, etc.
• How are companies navigating the source data monitoring from sites during these times
• What does the next 6-12 months look like from a risk-based approach to monitoring
UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com
TRACK 2
Patient Recruitment /
Patient Centricity & Virtual Trials
06
GO TO MENU PREVIOUS PAGE NEXT PAGE
Guillermo Caletti
Head of Clinical Operations
Boehringer Ingelheim
Pernilla Sandwall
Chief Operating Officer
InDex Pharmaceuticals
GC – Patient Recruitment
1:45pm - 2:45pm UK 3:15pm - 4:15pm UK 5:00pm - 6:00pm UKChristopher Varner
Project Lead, Virtual Trials
IQVIA
Using Virtual Trial Technology to Improve Site
Oversight
SPONSOR
Optimizing patient recruitment by utilising digital
health, RWE as well as traditional methods
ONLINE CLINICAL OPERATIONS
STRATEGY MEETING 2020
• Utilizing digital health and RWE • Challenges and opportunities
• Adapting recruitment strategies to the country and the site • Patient recruitment strategies – when and how to start
them in a Clinical Trial
• Site Selection – a Patient Recruitment Strategy
• Patient Advocacy Groups – Their interaction in Clinical
Trial Recruitment • Discuss PI and Site participation and buy-in of clinical trials• Discover the proper balance between system automation and site action
• Recognize the right model to support sites when introducing novel capabilities for clinical trials
8:45am - 9:45am NY
10:15am - 11:15am NY
UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com
TRACK 3
Emerging Biopharma
07
GO TO MENU PREVIOUS PAGE NEXT PAGE
Jessica Lee
SVP Clinical Operations & Global Integration
Inovio Pharmaceuticals
Developing a COVID19 vaccine
1:45pm - 2:45pm UK 3:15pm - 4:15pm UK
John Murray
Global Business Development Director SanaClis s.r.o.The evaluation of key approaches in regards to
risk sharing between all involved stakeholders of
a clinical study
SPONSOR
ONLINE CLINICAL OPERATIONS
STRATEGY MEETING 2020
• Development of COVID19 vaccine is an urgent public health need
• Opportunity for Emergency Use Authorization and associated implications
• GCP Challenges working in a pandemic
• To discuss the several models which aim to financially involve all parties, without compromise on the quality and budget of the study, thereby equally distributing and minimising risk of all involved stakeholders.
• How to ensure costs are controlled and the budget maintained, especially so for single molecule assets, whereby only limited finance is available.
• To effectively establish a joint and vested interest between both the investor, biotech and the CRO, thus incentivising all parties to ensure the study adheres to all aspects of the protocol, budget and timelines until the molecule is ready to proceed to the next phase or market authorisation.
8:45am - 9:45am NY
10:15am - 11:15am NY
Kylie Gyertson
Head of Cancer Clinical Trials
NHS Foundation Trust
Clinical Research in the Time of COVID-19
• The prospect of overwhelming COVID-19 admissions curtailed many NHS services during the first wave. Clinical Research was heavily impacted with many sites suspending research activity entirely – was this necessary?
• Many cancer trials offer a “safer” approach than standard treatment in the context of coronavirus concerns (eg oral
treatments over IV, neoadjuvant therapies delaying the need for surgery)
• Some cancer trials offer the possibility of a cure but involve perceived “high risk” activities such as inpatient stays and
potential side effects requiring ITU admissions (Cellular Therapies such as CAR-T)
• What have we learnt so far and what will be our approach second time around
UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com
TRACK 4
Clinical Outsourcing
08
GO TO MENU PREVIOUS PAGE NEXT PAGE
Magali Taiel
Chief Medical Officer
Gensight Biologics
Eyal Ron
CTO
AcuityBio
Ensuring strong and efficient vendor oversight
and communication
1:45pm - 2:45pm UK 3:15pm - 4:15pm UK 5:00pm - 6:00pm UKAnn Baker
VP, R&D Consulting IQVIAIncreasing the value impact of outsourcing in clinical
development
SPONSOR
Using Innovative Tools to Make a CRO a Trusted
Partner
ONLINE CLINICAL OPERATIONS
STRATEGY MEETING 2020
• How to balance efficient vendor oversight and internal resources
• Share examples with successful or unsuccessful communication; find the root causes
• What are the main factors impacting communication and work efficiency?
• Exploring innovative approaches to form an effective relationship with CROs
• Digital tools that can best support clear communication between sponsors and CROs
• Examining innovative management techniques to ensure relationships are maintained and study deliverables are met • Tools for maintaining contact and ensuring your trial is their priority
• Outsourcing as a key component of the Clinical Development Strategy. What are the drivers for outsourcing?
• Core vs. non-core decisions across functions, activities and infrastructures - Revisiting ownership of key capabilities • Driving increased value through Strategic Partnerships - Considerations for evolution and innovation of your model:
Co-design the best functional partnerships to deliver enhanced value
8:45am - 9:45am NY
10:15am - 11:15am NY
UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com
TRACK 5
Clinical Data/RWE
09
GO TO MENU PREVIOUS PAGE NEXT PAGE
Arun Mistry
Therapeutic Area Head
Mereo BioPharma
Can we generate real world evidence within
registration studies?
1:45pm - 2:45pm UK
3:15pm - 4:15pm UK
Stephanie Langouet
Chief Operations Officer
Cmed
How to overcome challenges of handling data
from multiple sources in clinical trials
SPONSOR
ONLINE CLINICAL OPERATIONS
STRATEGY MEETING 2020
• The notion that use of electronic health records is not limited to characterizing the risk of a safety signal
• Factors that influence whether electronic health records serve as the best RWD source
• Examples where information from electronic health records can serve as the basis for improving health outcomes
• Why is real world evidence important during development for a product?
• Importance of RWE pre-approval and post approval • How can RWE be generated in clinical trials?
• What other routes for RWE generation are possible?
8:45am - 9:45am NY 10:15am - 11:15am NY
William Blumentals
Head of Pharmacoepidemiology Sanofi Genzyme 5:00pm - 6:00pm UKMatching Electronic Health Records to RWD to
improve outcomes
12:00pm - 1:00pm NY
• With increasingly complex study designs the variety of data collected in clinical trials has grown rapidly. It is easier than ever before to collect vast amounts of data, but does that mean you should? Will the data you collect be usable and used? Study objectives and estimands drive the data your trial needs… or do they?
• The advancement of technologies and personalized
healthcare brings the challenge of collecting high quality data with integrity from multiple sources, including specialist biomarker labs, third party devices (monitors, holters etc), ePRO, wearables or electronic medical records.
• This round table will explore the challenges faced when trying to collect, process and analyze data efficiently from multiple sources to meet a variety of requirements.
UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com
TRACK 6
A.I & Disruptive
Technology
10
GO TO MENU PREVIOUS PAGE NEXT PAGE
Prasun Mishra
Chief Executive Officer
Agility Pharmaceuticals
Frank Leu
Chief Executive Officer
Novapeutics
AI and Disruptive Technologies in Accelerating
Clinical Trials
1:45pm - 2:45pm UK 3:15pm - 4:15pm UK 5:00pm - 6:00pm UKDavid Hadden
Co-Founder and Chief-Game-Changer Pro-ficiencyStarting and Managing Your Studies Remotely in a
Covid 19 World and Beyond
SPONSOR
Adopting Disruptive Technologies in Drug
Development are not Optional for Survival
ONLINE CLINICAL OPERATIONS
STRATEGY MEETING 2020
• The present state of clinical trials
• The need to accelerate the pace of clinical trials
• How AI and disruptive technologies could change every
stage of clinical trials • What’s the role of the investigator meeting? • PI engagement as an enrollment strategy • Simulation as the new training standard
• Enhance supply forecasting and product tracking /
authentication using new technologies in drug development, such as in the supply chain management.
• The risk of all stakeholders being ‘risk adverse’ in adopting disruptive technologies and processes.
• Blockchain, AI, deep data Mining, internet of things, and decentralized trials as the emerging healthcare technologies and processes
8:45am - 9:45am NY
10:15am - 11:15am NY
UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com
11
2019 ATTENDEES
GO TO MENU PREVIOUS PAGE
ONLINE CLINICAL OPERATIONS
STRATEGY MEETING 2020
COMPANY
JOB TITLE
Agenus Director of Clinical Data Management
Agenus Director, Clinical Operations
Alexion Pharmaceuticals Associate Director Global Strategic Sourcing
Alexion Pharmaceuticals Director, Global Clinical Operations
Alexion Pharmaceuticals SVP, Developmental Operations and Quantitative Sciences
Alnylam Pharmaceuticals Associate Director Clinical Operations
AOBiome Therapeutics Head of Clinical Operations
AOBiome Therapeutics Senior Manager, Global Clinical Operations
AOBiome Therapeutics SVP Therapeutics
Aprea Therapeutics VP, Global Clinical Operations
Arcellx VP Clinical Development
Astellas Institute for
Regenerative Medicine Associate Director, Clinical Operations Astellas Institute for
Regenerative Medicine Director, Clinical and Program Management Axcella Health VP Head of Quality
Bellerophon Therapeutics Director, Clinical Operations
Bellerophon Therapeutics VP, Clinical Operations & Administration
BERG Chief Scientific Officer & SVP Clinical and Translational Sciences
Bill & Melinda Gates Medical
Research Institute Head of Project Management & Clinical Operations Biogen Vice President, Global Clinical Operations
Bluebirdbio Vice President, Head of Clinical Operations
Boston Biomedical Associate Director Clinical Operations
C4 Therapeutics Head of Clinical Operations
Cerevance Senior VP, Clinical and Translational Medicine
Cerevel Therapeutics Director,Clinical Operations -- Oversight
Cerevel Therapeutics Head of Scientific Operations
Cerevel Therapeutics Vice President, Clinical Operations and Quality Management
Cold Genesys, Inc. Chief Scientific Officer
CRISPR Therapeutics Director, Clinical Outsourcing
Cyteir Vice President Clinical Operations
Eisai Co., Ltd. Senior Director
Eisai Co., Ltd. Assoc. Director, Clinical Operations
EMD Serono Inc. Clinical Trial Lead
EMD Serono Inc. Director, Sourcing Strategy & Operations
EMD Serono Inc. VP, Head of Operations, New Businesses
EMD Serono Inc. Director, Clinical Innovation
Enanta Pharmaceuticals Director, Clinical Operations
FORMA Therapeutics Head of Clinical Operations
Fractal Therapeutics CEO and Founder
Gelesis Chief Technical Officer
COMPANY
JOB TITLE
Gemini Therapeutics, Inc. Vice President, Clinical Operations
Gemini Therapeutics, Inc. Director, Program Management
Goldfinch Bio Chief Medical Officer
Goldfinch Bio Vice President, Clinical and Translational Nephrology
GSK Head of Clinical Operations Americas
GSK/TESARO Director, Clinical Operations
GSK/TESARO VP, GCSD TA Head for Oncology
Harbour Biomed Chief Strategy Officer
ImmunoGen, Inc. Associate Director
Immunomedics Clinical Program Study Director
Incyte Executive Director, Clinical Operations
Infinity Pharmaceuticals Head of Clinical Operations
Ipsen Bioscience, Inc. AD, Clinical Project Managment
Ipsen Bioscience, Inc. Senior Director; Head, Clinical Operations – Oncology
Ironwood Pharmaceuticals Clinical Operations
Ironwood Pharmaceuticals Director, Head of Clinical Operations
Kura Oncology Director, Clinical Operations
L.E.A.F Therapeutics Vice President Research and Development Operations
Magenta Therapeutics Associate Director Clinical Operations
Magenta Therapeutics Vice President, Head of Clinical Development Operations
Merck Early Clinical Scientist
Moderna Therapeutics Vice President, Head Therapeutic Operations
Momenta Pharmaceuticals Director of Clinical Contracts and Vendor Management
Momenta Pharmaceuticals Director, Clinical Development Operations
Mylan Senior Director
NIBR Associate Director, Strategic Feasibility
Novapeutics CEO and Founder
Novartis Associate Clinical Trial Lead
Novartis Clinical Project Associate
Novartis Clinical Trial Leader
Novartis Director of Disruptive Technologies
Novartis Global Head Strategy and Operations, Clinical Quality, Novartis
Novartis Translational Project Manager
Ovid Therapeutics Associate Director, Clinical Data Management / Senior Manager
Ovid Therapeutics Associate Director, Clinical Operations
Ovid Therapeutics Director, Global Clinical Operations
Ovid Therapeutics Clinical Trial Operations Manager
Ovid Therapeutics VP, Global Clinical Operation
Pear Therapeutics Director Clinical Operations
COMPANY
JOB TITLE
Pfizer Director, Portfolio Analytics
Pieris Pharmaceuticals Associate Director, Clinical Operations
Proteostasis Therapeutics, Inc. Senior Medical Director
Radius Health Senior Medical Director
Relay Therapeutics Vice President, Clinical Development
Repare Therapeutics Inc Chief Medical Officer
Repare Therapeutics Inc Director, Translational Sciences
Repare Therapeutics Inc Head of Clinical Operations
Sage Therapeutics Associate Director, Patient Recruitment and Trial Awareness
Sanofi Vice President & Medical Head, Oncology & Transplant
Sarepta Therapeutics Associate Director Clinical Systems and Analytics
Sarepta Therapeutics Associate Director Clinical Performance
Sarepta Therapeutics Clinical Program Lead
Sarepta Therapeutics Executive Director, Clinical Operations
Sarepta Therapeutics Global Clinical Trial Manager
Sarepta Therapeutics Vice President, Global Medical Affairs
Sigilon Therapeutics Director Clinical Operations
Solace Therapeutics Vice President, Clinical Affairs
Spring Bank Pharmaceuticals Associate Director Program Management
Spring Bank Pharmaceuticals VP Non-Clinical and Translational Research
Stoke Therapeutics Director of Clinical Development
Stoke Therapeutics VP, Head of Clinical Operations
Takeda Director, Clinical Program Management
Takeda Head of Partnership Engagement
Takeda Vice President, Head of Clinical Operations
Takeda Associate Director, Clinical Operations Program Lead
Takeda Clinical Operations Program Leader
Takeda Director, Strategic Partnership
Takeda Global Development Operations, Early Clinical Operations
Takeda Head - Clinical Development Services
Takeda Senior Clinical Operations Clinical Lead
Takeda Senior Solutions Arch, Global Development
Takeda Pharmaceuticals Associate Medical Director
Takeda Pharmaceuticals Vice President, Head of Global Development Support
Tremeau Pharmaceuticals, Inc. Head Clinical Operations
Unum Therapeutics Senior Clinical Trial Manager
Unum Therapeutics Director, Clinical Operations
Vertex Pharmaceuticals Senior Director, Head of Medical Writing
Vigeo Therapeutics Head Of Clinical Operations
Visterra, Inc. Clinical Trial Associate
